PMC:7195088 / 23182-23357 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T114","span":{"begin":166,"end":174},"obj":"Disease"}],"attributes":[{"id":"A114","pred":"mondo_id","subj":"T114","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"The manuscript is publicly available but still to be peer reviewed [30] • Comparison of favipiravir vs. tocilizumab vs. favipiravir plus tocilizumab in patients with COVID-19."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T114","span":{"begin":53,"end":57},"obj":"http://purl.obolibrary.org/obo/CLO_0008416"},{"id":"T115","span":{"begin":53,"end":57},"obj":"http://purl.obolibrary.org/obo/CLO_0050081"}],"text":"The manuscript is publicly available but still to be peer reviewed [30] • Comparison of favipiravir vs. tocilizumab vs. favipiravir plus tocilizumab in patients with COVID-19."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T275","span":{"begin":88,"end":99},"obj":"Chemical"},{"id":"T276","span":{"begin":104,"end":115},"obj":"Chemical"},{"id":"T277","span":{"begin":120,"end":131},"obj":"Chemical"},{"id":"T278","span":{"begin":137,"end":148},"obj":"Chemical"}],"attributes":[{"id":"A275","pred":"chebi_id","subj":"T275","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A276","pred":"chebi_id","subj":"T276","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A277","pred":"chebi_id","subj":"T277","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A278","pred":"chebi_id","subj":"T278","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"}],"text":"The manuscript is publicly available but still to be peer reviewed [30] • Comparison of favipiravir vs. tocilizumab vs. favipiravir plus tocilizumab in patients with COVID-19."}

{"project":"LitCovid-sentences","denotations":[{"id":"T171","span":{"begin":0,"end":175},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The manuscript is publicly available but still to be peer reviewed [30] • Comparison of favipiravir vs. tocilizumab vs. favipiravir plus tocilizumab in patients with COVID-19."}